Treatment of Myeloma Cast Nephropathy (MCN): A Randomized Trial Comparing Intensive Haemodialysis (HD) with High Cut-Off (HCO) or Standard High-Flux Dialyzer in Patients Receiving a Bortezomib-Based Regimen (the MYRE Study, by the Intergroupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT))
Frank Bridoux(Université de Poitiers), Jean‐Paul Fermand(Sorbonne Université), Bertrand Arnulf(Université Paris Cité), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Brigitte Kolb(Centre Hospitalier Universitaire de Reims), Thierry Lamy(Centre Hospitalier Universitaire de Lille), Bertrand Joly(Centre Hospitalier Sud Francilien), Sylvie Chevret(Saint Louis University Hospital), Brigitte Pegourié(Centre Hospitalier Universitaire de Grenoble), Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Lofti Benboubker(Centre Hospitalier Universitaire de Tours), Karine Augeul-Meunier(Centre Hospitalier Universitaire de Saint-Étienne)
Cited by 15
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
|The Lancet|2012|1k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809